CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Prothrombin complex concentrate reverses the anticoagulant effect of rivaroxaban in healthy volunteers
Authors
Elise S. Eerenberg
Pieter W. Kamphuisen
+3 more
Marcel Levi
Joost C.M. Meijers
Meertien K. Sijpkens
Publication date
19 November 2010
Publisher
Abstract
Background: Rivaroxaban is a novel oral antithrombotic agent in the class of specific factor Xa inhibitors, and is licensed in Europe and Canada for the prevention of venous thromboembolism after elective orthopedic surgery. Despite its stable pharmacokinetic and pharmacodynamic profile, immediate reversal may be required in case of a major bleeding or emergency surgery. No specific antidote is currently available, although Prothrombin Complex Concentrate (PCC) seems effective in animal studies. This study is the first to investigate the ability of PCC to reverse the antithrombotic effect of Rivaroxaban in humans. Methods: In a randomized, double-blind, placebo-controlled trial, twelve healthy male subjects received Rivaroxaban 20mg twice daily for two and a half days. One group (n=6) was then randomized to receive a single bolus of 50 IU/kg PCC (Co-fact©, Sanquin, the Netherlands) while the other group (n=6) was given a similar volume of saline. Results: The prothrombin time (PT) was significantly prolonged by Rivaroxaban (15.8 sec ± 1.3 versus 12.3 ± 0.7 at baseline; p<0.001). Immediately after the infusion of PCC, the PT normalised almost completely (12.8 ± 1.0; p<0.001), which was sustained for 24 hours. Saline did not reverse the PT prolongation (16.2 ± 0.8; p= 0.4). Furthermore, Rivaroxaban inhibited the endogenous thrombin potential (ETP) (51% ± 22, baseline 92 ± 22; p= 0.002), with normalisation after administration of PCC (114 ± 26; p<0.001), but not after saline (41 ± 6; p= 0.2). Conclusions: This study provides the first data that Prothrombin Complex Concentrate reverses the anticoagulant effect of Rivaroxaban in humans and may serve as an antidote for the new oral factor Xa inhibitors (Figure Presented)
Similar works
Full text
Available Versions
University of Groningen Research Database
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.rug.nl:publications/8...
Last time updated on 10/02/2018
ARTS repository - University of Groningen
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.rug.nl:openaire_cris_...
Last time updated on 22/04/2023
ARTS repository - University of Groningen
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.rug.nl:publications/8...
Last time updated on 03/06/2022
University of Groningen
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.rug.nl:publications/8...
Last time updated on 29/10/2019
NARCIS
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 09/03/2017